Home›Ribociclib

Ribociclib

Route: Oral

5 interactions on record

Ribociclib has 5 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyp3a Inducers, Letrozole And Ribociclib, Mao Inhibitors. Patients taking Ribociclib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 5
Major: 4
Moderate: 1

Major (4)

Ribociclib + Cyp3a Inducers— Strong CYP3A inducers decrease ribociclib plasma exposure. Avoid concomitant use and consider alternative medications.
Ribociclib + Letrozole And Ribociclib— 7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhi…
Ribociclib + Mao Inhibitors— Strong CYP3A inhibitors increase ribociclib exposure, which may increase incidence and severity of adverse reactions inc…
Ribociclib + Voriconazole— Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabr…

Moderate (1)

Ribociclib + Sensitive Cyp3a Substrates— KISQALI increases exposure of CYP3A4 substrates. Monitor for increased adverse reactions and consider dose reduction of …

Ribociclib + Cyp3a Inducers⚠️Major

Strong CYP3A inducers decrease ribociclib plasma exposure. Avoid concomitant use and consider alternative medications.

Ribociclib + Letrozole And Ribociclib⚠️Major

7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. ( 7.4 ) 7.1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure [see Clinical Pharmacology (12.3)] . Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation [see Warnings and Precautions (5.3)] .

Ribociclib + Mao Inhibitors⚠️Major

Strong CYP3A inhibitors increase ribociclib exposure, which may increase incidence and severity of adverse reactions including QTcF prolongation. Avoid concomitant use or reduce KISQALI dose.

Ribociclib + Voriconazole⚠️Major

Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of VFEND.

Ribociclib + Sensitive Cyp3a Substrates🟡Moderate

KISQALI increases exposure of CYP3A4 substrates. Monitor for increased adverse reactions and consider dose reduction of the CYP3A substrate.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.